Online first
Research paper
Published online: 2024-02-01

open access

Page views 212
Article views/downloads 190
Get Citation

Connect on Social Media

Connect on Social Media

Effects of intravenous nicardipine followed by oral labetalol in combination with nifedipine controlled-release tablet on severe peripartum hypertension

Lan Lan1, Yunsheng Yan1, Haifeng Qi1, Jiali Qin1, Lan Li1, Shengwen Gan1, Ruoxuan Zhang2, Yaozong Zhang13


Objectives: To investigate the effects of intravenous nicardipine as initial therapy and oral labetalol combined with nifedipine controlled-release tablet as subsequent treatment of severe peripartum hypertension.

Material and methods: Intravenous nicardipine was delivered as the initial treatment, after the target blood pressure (BP) had been achieved, oral labetalol was used to maintain the target BP. If oral labetalol failed to maintain the target BP, oral labetalol combined with nifedipine controlled-release tablet was used.

Results: A total number of 131 patients were enrolled. The target BP (BP < 140/90 mmHg) was achieved in all patients within 60 minutes by intravenous nicardipine. After receiving labetalol orally, the target BP was maintained in nine patients. However, in 104 patients, we had to combine oral labetalol and nifedipine controlled-release tablet due to re-elevation of their systolic BP to 140–159 mmHg. In 18 patients, we restarted intravenous nicardipine because their systolic BP re-elevated above 160 mm Hg. Among the 104 patients who received oral labetalol and nifedipine controlled-release tablet, the target BP was achieved and maintained in 96 patients, and eight patients had to restart nicardipine. Of the total number of 26 patients in whom intravenous nicardipine was resumed, the target BP was successfully maintained in 22 patients with oral labetalol combined with nifedipine controlled-release tablet.

Conclusions: Intravenous nicardipine rapidly and safely lowered severe peripartum hypertension. As subsequent therapy, oral labetalol combined with nifedipine controlled-release tablet protocol may be applied to effectively maintain a target BP.

Article available in PDF format

View PDF Download PDF file


  1. Wiles K, Damodaram M, Frise C. Severe hypertension in pregnancy. Clin Med (Lond). 2021; 21(5): e451–e456.
  2. Papademetriou V, Stavropoulos K, Patoulias D, et al. Hypertension in pregnancy: unanswered questions. Curr Pharm Des. 2021; 27(36): 3795–3803.
  3. Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2022; 226(2S): S1211–S1221.
  4. Qi H, Qin J, Ren Li, et al. Efficacy of low-dose nicardipine for emergent treatment of severe postpartum hypertension in maternal intensive care units: an observational study. Pregnancy Hypertens. 2020; 21: 43–49.
  5. Nij Bijvank SW, Hengst M, Cornette JC, et al. Nicardipine for treating severe antepartum hypertension during pregnancy: nine years of experience in more than 800 women. Acta Obstet Gynecol Scand. 2022; 101(9): 1017–1025.
  6. van de Vusse D, Mian P, Schoenmakers S, et al. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. Eur J Clin Pharmacol. 2022; 78(11): 1763–1776.
  7. Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022; 386(19): 1817–1832.
  8. Tolcher MC, Fox KA, Sangi-Haghpeykar H, et al. Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure. Am J Obstet Gynecol. 2020; 223(3): 441.e1–441.e8.
  9. Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022; 27: 148–169.
  10. Brown MA, Magee LA, Kenny LC, et al. International Society for the Study of Hypertension in Pregnancy (ISSHP). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018; 13: 291–310.
  11. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020; 135(6): e237–e260.
  12. Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019; 394(10203): 1011–1021.
  13. Vadhera RB, Pacheco LD, Hankins GDV. Acute antihypertensive therapy in pregnancy-induced hypertension: is nicardipine the answer? Am J Perinatol. 2009; 26(7): 495–499.
  14. Nooij LS, Visser S, Meuleman T, et al. The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. Curr Pharm Biotechnol. 2014; 15(1): 64–69.
  15. Magee LA, Namouz-Haddad S, Cao V, et al. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015; 14(3): 453–461.
  16. Brown MA, Buddle ML, Farrell T, et al. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol. 2002; 187(4): 1046–1050.
  17. Giannubilo SR, Bezzeccheri V, Cecchi S, et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet. 2012; 286(3): 637–642.
  18. Damasceno A, Sevene E, Patel S, et al. Nifedipine-retard versus nifedipine-capsules for the therapy of hypertensive crisis in black patients. J Cardiovasc Pharmacol. 1998; 31(1): 165–169.
  19. Sathya Lakshmi B, Dasari P. Oral nifedipine versus intravenous labetalol in hypertensive urgencies and emergencies of pregnancy: a randomized clinical trial. Obstet Med. 2012; 5(4): 171–175.
  20. Castaneda MP, Walsh CA, Woroniecki RP, et al. Ventricular arrhythmia following short-acting nifedipine administration. Pediatr Nephrol. 2005; 20(7): 1000–1002.
  21. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018; 84(9): 1906–1916.
  22. Binggeli C, Corti R, Sudano I, et al. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension. 2002; 39(4): 892–896.
  23. Croom KF, Wellington K. Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs. 2006; 66(4): 497–528.
  24. Bouchard J, Shepherd G, Hoffman RS, et al. EXTRIP workgroup. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care. 2021; 25(1): 201.
  25. Rotella JA, Greene SL, Koutsogiannis Z, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020; 58(10): 943–983.